Free Newsletter
Judge dismisses Lousiana's Rezulin suit
Hear that sigh of relief from Pfizer? A New York judge tossed out a lawsuit pitting the State of Louisiana against Pfizer over the diabetes drug Rezulin, which was pulled from the market in 2000 because of liver toxicity problems.
Louisiana was trying to recover Medicaid payments for the drug and the costs of treating illnesses Rezulin caused. And it's only one of many lawsuits filed in the wake of the drug's withdrawal. Pfizer acquired the lawsuits in its buyout of Warner-Lambert; it settled many of the personal injury claims in 2003.
- see the Trading Markets report
Related Articles:
Supreme Court to hear Pfizer liability case. Report
A look inside Pfizer's biotech center. Report
More stories about Pfizer
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: